Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Studies in neuroscience with applications to humans offer clues about what makes us start eating, and when we stop.

GLP-1 medicines can be helpful tools for the treatment of obesity and for other important health goals, but they’re not for ...

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

Ozempic, originally for type 2 diabetes, has surged in popularity in North America as a weight-loss solution, sparking a ...

Many people experience a serious return of appetite, cravings and weight after coming off Ozempic, and having read far too ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...